Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glenmark gets FDA nod for calcipotriene ointment

This article was originally published in Scrip

Executive Summary

Glenmark Generics, a US subsidiary of India's Glenmark, has received final approval from the US FDA for calcipotriene ointment 0.005%, a generic version of Leo Pharmaceuticals' plaque psoriasis treatment, Dovonex. Leo Pharmaceuticals marketed Dovonex ointment from December 1993 until April 2007, when the product was discontinued due to lack of commercial viability, Glenmark said. Leo still markets a line of Dovonex products including a cream and a topical solution. Dovonex reported peak sales of about $93 million in 2006.

You may also be interested in...



Wockhardt Puts Up Superbug Fight With Punchy Broad Spectrum Antibiotic

Wockhardt has received approvals in India for two novel broad spectrum antibiotics with "advantageous" safety features over older MRSA drugs and the firm hopes to take them to other emerging markets as well, with China on the radar.

India 2019 – R&D Highs, Compliance Woes And Other Lows

2019 saw Indian companies advance innovation efforts and build and expand their specialty portfolios and biosimilars businesses. But manufacturing compliance issues weighed down several firms while on another front charges against the Singh brothers of Ranbaxy escalated.

Glenmark Readies New Diabetes Combo In India

Glenmark is working on a combination of remogliflozin and teneligliptin in India, which if successful could bring additional sting to its portfolio in the country's bustling diabetes segment. But Boehringer-Lilly’s rival Glyxambi already has a head-start.

Topics

Related Companies

UsernamePublicRestriction

Register

SC008232

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel